India Exchange Filings

Q2 FY27 Results and Board Meeting Highlights

Supriya Lifescience Ltd approves Q2 FY27 results with ₹206.3 crore revenue and appoints Mangesh Vaze as COO

  • Revenue rose 8.7% sequentially and 3.2% year on year; calculated EBITDA operating margin was 23.1%.
  • Net profit was ₹29.3 crore, up 21.7% sequentially and down 42.0% year on year.
  • Vaze’s appointment as Chief Operating Officer and Senior Management Personnel is effective 6 November 2026.
  • No exceptional items were reported; the limited review noted no material misstatement.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.